Scar PT Gel (Pentoxifylline / Triamcinolone Acetonide) (30 mL)

Scar PT Gel is a specially formulated topical product designed to help improve the appearance of scars, surgical marks, and other skin imperfections. It supports the natural healing process by nourishing the skin and encouraging the growth of healthy new cells. The lightweight, non-greasy formula is easily absorbed, providing comfort and hydration while helping the skin repair itself. With regular use, it can reduce the visibility of scars and improve the texture and smoothness of the skin.

Scar PT Gel works by promoting skin regeneration and providing essential moisture to damaged areas. Its active ingredients help stimulate the production of new skin cells, while moisturizing components ensure the skin stays hydrated and supple. The gel also helps to calm inflammation and reduce redness, offering relief from discomfort during the healing process. Over time, continuous use improves the color, texture, and thickness of scars, making them less noticeable and enhancing the skin’s overall appearance.

Scar PT Gel should be used with caution in certain situations. Individuals who are allergic to any of the ingredients should consult a healthcare professional before use. The gel should not be applied to open wounds, deep cuts, or infected areas as this may cause irritation or worsen the condition. If you experience unusual itching, redness, or burning, stop using the product immediately and seek medical advice. Avoid applying the gel near the eyes, nose, or mouth, and keep it out of reach of children. Always follow the recommended usage instructions and avoid applying excessive amounts.

While Scar PT Gel is generally safe, some users may experience mild side effects. These may include temporary redness, itching, dryness, or a slight burning sensation at the application site. People with sensitive skin or allergies may experience increased irritation. If you notice serious reactions such as blistering, severe itching, or peeling skin, discontinue use and consult a healthcare provider. In most cases, any discomfort is mild and resolves shortly after stopping the application.

Pregnant and breastfeeding women should consult their doctor before using Scar PT Gel. Some ingredients may be absorbed through the skin, and hormonal changes during pregnancy may increase skin sensitivity. While the product is generally considered safe for use, it is important to discuss its use with a healthcare professional to ensure it does not affect the mother or child. With medical guidance, it can be used safely, but caution is advised.

Store this medication in its original container at 68°F to 77°F (20°C to 25°C) and away from heat, moisture and light. Keep all medicine out of the reach of children. Throw away any unused medicine after the beyond use date. Do not flush unused medications or pour down a sink or drain.

1. “1.Dennenhoffer MA, Rozek S. Pentoxifylline in sickle cell anemia. Drug Intel Clin Pharm 1987;21:620.
2. Vinik AI, Holland MT, Le Beau JM, et al. Diabetic neuropathies. Diabetes Care 1992;15:1926-75.
3. Schimmer B, Parker K. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman JG, Limbird LE, Molinoff PB, et al., eds. Goodman and Gilman’s the Pharmacological Basis of Therapeutics, 10th edition. New York: McGraw Hill, 2001;1649-1674.
4. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond). 1998;94(6):557-572.
5. National Asthma Education and Prevention Program Expert Panel 3. Expert panel report 3: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health. National Heart, Lung, and Blood Institute; 2007 Aug. NIH Publication No. 07-4051.
6. Pentoxifylline (Trental) tablets package insert. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; Oct 2007.
7. Witter FR, Smith RV. The excretion of pentoxifylline and its metabolites into human breast milk. Am J Obstet Gynecol. 1985;151:1094-7.
8. Bond DW, Charlton CPJ. Benign intracranial hypertension secondary to nasal fluticasone propionate. BMJ 2001;322 (7291):987.
9. Patradoon-Ho P, Gunasekera H, Ryan MM. Inhaled corticosteroids, adrenal suppression and benign intracranial hypertension. Med J Aust 2006;185:279-280
10. Triamcinolone acetonide ointment package insert. Melville, NY: E. Fougera & Co., 2011 Oct.
11. Azmacort (triamcinolone acetonide) package insert. North Chicago, IL: Abbott Laboratories; 2007 Sept.
12. Kenalog-40 (triamcinolone acetonide) injection package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2018 Mar.
13. Shulman DI, Palmert MR, Kemp SF. Adrenal insufficiency: still a cause of morbidity and death in childhood. Pediatrics 2007;119(2):e484-494.
14. Triamcinolone acetonide cream package insert. Melville, NY: E. Fougera & Co.; 2011 Sept
15. Nasacort AQ (triamcinolone acetonide) nasal spray package insert. Bridgewater, NJ: Sanofi-aventis U.S. LLC; 2013 July.
16. Nasacort Allergy 24HR (triamcinolone acetonide) OTC nasal spray package insert. Chattanooga, TN: Chattem, Inc., a wholly-owned subsidiary of Sanofi-Aventis; 2016 Sept.
17. Zilretta (triamcinolone acetonide extended-release injectable suspension). Burlington, MA: Flexion Therapeutics, Inc.; 2019 Dec.
18. Hengge UR, Ruzicka T, Schwartz RA. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006;54:1-15.
19. Morley KW, Dinulos JG. Update on topical glucocorticoid use in children. Curr Opin Pediatr 2012;24(1):121-128
20. Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med 1995;98:196-207.
21. Kenalog (triamcinolone acetonide) topical aerosol package insert. Jacksonville, FL: Ranbaxy; 2011 July.
22. Triesence (triamcinolone acetonide injection for ophthalmic use) package insert. Fort Worth, TX: Alcon Laboratories, Inc.; 2018 Dec.
23. Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol. 2014;70:401.e1-14. Review.
24. The American Geriatrics Society 2019 Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2019;00:1-21.
25. Health Care Financing Administration. Interpretive Guidelines for Long-term Care Facilities. Title 42 CFR 483.25(l) F329: Unnecessary Drugs. Revised 2015.
26. Zilretta (triamcinolone acetonide extended-release injectable suspension). Burlington, MA: Flexion Therapeutics, Inc.; 2019 Dec.
27. Aristospan (triamcinolone hexacetonide) 5 mg/ml injection package insert. Princeton, NJ: Sandoz Inc.; 2014 Apr.
28. NAEPP Working Group Report on Managing Asthma During Pregnancy. Recommendations for Pharmacologic Treatment-Update 2004. NIH Publication No. 05-3279. Bethesda, MD: U.S. Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute, 2004
29. Greenberger PA, Patterson R. The management of asthma during pregnancy and lactation. Clin Rev Allergy 1987;5:317-24.
30. Ellsworth A. Pharmacotherapy of asthma while breastfeeding. J Hum Lact 1994;10:39-41.
31. Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. J Am Acad Dermatol. 2014;70:417.e1-10. Review.
32. Trental (pentoxifylline) package insert. Bridgewater, NJ: Sanofi-Aventis Pharmaceuticals Inc.; 2010 Jun.
33. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994;236:619-32.
34. Abramson N, Melton B. Leukocytosis: basic of clinical assessment. Am Fam Physician 2000;62:2053-60.
35. Shoenfeld Y, Gurewich Y, Gallant LA, et al. Prednisone-induced leukocytosis. Influenced of dosage, method and duration of administration on the degree of leukocytosis. Am J Med 1981;71:773-8.
36. Prednisone tablet package insert. Salisbury, MD: Cadista Pharmaceuticals Inc.; 2016 Mar.
37. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004;141:764-70.
38. Kenalog-10 (triamcinolone acetonide) injection package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2018 Jun.
39. Cumming RG, Mitchell P, Leeder SR, et al. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997;337:8-14.
40. Trivaris (triamcinolone acetonide injectable suspension) package insert. Irvine, CA: Allergan, Inc.; 2008 Jun.”